World Health Organization (WHO): Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019urisimplehttps://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed November 2, 2020.

Liu YC, Kuo RL and Shih SR: COVID-19: The first documented coronavirus pandemic in history. Biomed J. 43:328–333. 2020. View Article : Google Scholar : PubMed/NCBI

Tsay SF, Kao CC, Wang HH and Lin CC: Nursing's response to COVID-19: Lessons learned from SARS in Taiwan. Int J Nurs Stud. 108:1035872020. View Article : Google Scholar : PubMed/NCBI

Chang CL and McAleer M: Alternative global health security indexes for risk analysis of COVID-19. Int J Environ Res Public Health. 17:31612020. View Article : Google Scholar :

Hsu YC, Liu YA, Lin MH, Lee HW, Chen TJ, Chou LF and Hwang SJ: Visiting policies of hospice wards during the COVID-19 pandemic: An environmental scan in Taiwan. Int J Environ Res Public Health. 17:28572020. View Article : Google Scholar :

Schwartz J, King CC and Yen MY: Protecting healthcare workers during the coronavirus disease 2019 (COVID-19) outbreak: lessons from Taiwan's severe acute respiratory syndrome response. Clin Infect Dis. 71:858–860. 2020. View Article : Google Scholar : PubMed/NCBI

Wu YC, Chen CS and Chan YJ: The outbreak of COVID-19: An overview. J Chin Med Assoc. 83:217–220. 2020. View Article : Google Scholar : PubMed/NCBI

U.S. Food & Drug Administration (FDA): Coronavirus Disease 2019 (COVID-19). https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalizedurisimplehttps://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized. Accessed August 28, 2020.

Park SE: Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 63:119–124. 2020. View Article : Google Scholar : PubMed/NCBI

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al: Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 382:1199–1207. 2020. View Article : Google Scholar : PubMed/NCBI

Day M: Covid-19: Identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ. 3:m11652020. View Article : Google Scholar

Chang TH, Wu JL and Chang LY: Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. J Formos Med Assoc. 119:982–989. 2020. View Article : Google Scholar : PubMed/NCBI

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 395:1054–1062. 2020. View Article : Google Scholar : PubMed/NCBI

Lin CT, Bookman K, Sieja A, Markley K, Altman RL, Sippel J, Perica K, Reece L, Davis C, Horowitz E, et al: Clinical informatics accelerates health system adaptation to the COVID-19 pandemic: Examples from Colorado. J Am Med Inform Assoc. Jul 20–2020.Epub ahead of print. View Article : Google Scholar

Liu X, Zhang R and He G: Hematological findings in corona-virus disease 2019: Indications of progression of disease. Ann Hematol. 99:1421–1428. 2020. View Article : Google Scholar : PubMed/NCBI

Ippolito D, Maino C, Pecorelli A, Allegranza P, Cangiotti C, Capodaglio C, Mariani I, Giandola T, Gandola D, Bianco I, et al: Chest X-ray features of SARS-CoV-2 in the emergency department: A multicenter experience from northern Italian hospitals. Respir Med. 170:1060362020. View Article : Google Scholar : PubMed/NCBI

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020. View Article : Google Scholar : PubMed/NCBI

Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, Lai WY, Yang DM, Chou SJ, Yang YP, et al: A review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci. 21:26572020. View Article : Google Scholar :

Davis B, Rothrock AN, Swetland S, Andris H, Davis P and Rothrock SG: Viral and atypical respiratory co-infections in COVID-19: A systematic review and meta-analysis. J Am Coll Emerg Physicians Open. 1:533–548. 2020. View Article : Google Scholar

Oliva A, Siccardi G, Migliarini A, Cancelli F, Carnevalini M, D'Andria M, Attilia I, Danese VC, Cecchetti V, Romiti R, et al: Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: A case series and review of the literature. Infection. Jul 28–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, et al: Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis. 13:752–761. 2013. View Article : Google Scholar : PubMed/NCBI

Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, Nguyen TT, Cao TM and Pham QD: Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 382:872–874. 2020. View Article : Google Scholar : PubMed/NCBI

Rothan HA and Byrareddy SN: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 109:1024332020. View Article : Google Scholar : PubMed/NCBI

Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q and Miao H: Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct Target Ther. 5:332020. View Article : Google Scholar : PubMed/NCBI

Su YJ and Lai YC: Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan. Travel Med Infect Dis. 36:1016252020. View Article : Google Scholar : PubMed/NCBI

Sung YY, Wu YC, Li CY, Hsu CY, Hsu CY, Liang ST, Huang WC, Pan KY, Tsai JH and Yen YH: Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (5th edition) Ministry of Health and Welfare. Taiwan: Centers for Disease Control; 2020, https://www.cdc.gov.tw/File/Get/-ewtg9-RCAetCPKR4_rnCwurisimplehttps://www.cdc.gov.tw/File/Get/-ewtg9-RCAetCPKR4_rnCw. Accessed March 26, 2020.

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, et al: Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 27:325–328. 2020. View Article : Google Scholar : PubMed/NCBI

Singhal T: A Review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 87:281–286. 2020. View Article : Google Scholar : PubMed/NCBI

Li G and De Clercq E: Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 19:149–150. 2020. View Article : Google Scholar : PubMed/NCBI

National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI): NCBI SARS-CoV-2 Resources. https://www.ncbi.nlm.nih.gov/Structure/SARS-CoV-2.htmlurisimplehttps://www.ncbi.nlm.nih.gov/Structure/SARS-CoV-2.html. Accessed October 27, 2020.

Hoffmann M, Kleine-Weber H and Pöhlmann S: A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 78:779–784.e5. 2020. View Article : Google Scholar : PubMed/NCBI

Schoeman D and Fielding BC: Is there a link between the pathogenic human coronavirus envelope protein and immunopathology? A review of the literature. Front Microbiol. 11:20862020. View Article : Google Scholar : PubMed/NCBI

Malik YA: Properties of coronavirus and SARS-CoV-2. Malays J Pathol. 42:3–11. 2020.PubMed/NCBI

Mu J, Xu J, Zhang L, Shu T, Wu D, Huang M, Ren Y, Li X, Geng Q, Xu Y, et al: SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells. Sci China Life Sci. 63:1–4. 2020. View Article : Google Scholar : PubMed/NCBI

Baez-Santos YM, Mielech AM, Deng X, Baker S and Mesecar AD: Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J Virol. 88:12511–12527. 2014. View Article : Google Scholar : PubMed/NCBI

Sakai Y, Kawachi K, Terada Y, Omori H, Matsuura Y and Kamitani W: Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication. Virology. 510:165–174. 2017. View Article : Google Scholar : PubMed/NCBI

Angelini MM, Akhlaghpour M, Neuman BW and Buchmeier MJ: Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio. 4:e00524–13. 2013. View Article : Google Scholar : PubMed/NCBI

Snijder EJ, Decroly E and Ziebuhr J: The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv Virus Res. 96:59–126. 2016. View Article : Google Scholar : PubMed/NCBI

Rathnasinghe R, Karlicek RF, Schotsaert M, Koffas MA, Arduini B, Jangra S, Wang B, Davis JL, Alnaggar M, Costa A, et al: Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultra-violet C (UVC) irradiation device. medRxiv. View Article : Google Scholar

Boopathi S, Poma AB and Kolandaivel P: Novel 2019 corona-virus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. Apr 30–2020.Epub ahead of print. View Article : Google Scholar

Verdecchia P, Cavallini C, Spanevello A and Angeli F: The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 76:14–20. 2020. View Article : Google Scholar : PubMed/NCBI

Chen WH, Strych U, Hotez PJ and Bottazzi ME: The SARS-CoV-2 vaccine pipeline: An overview. Curr Trop Med Rep. Mar 3–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

Chan VS, Chan KY, Chen Y, Poon LL, Cheung AN, Zheng B, Chan KH, Mak W, Ngan HY, Xu X, et al: Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nat Genet. 38:38–46. 2006. View Article : Google Scholar

Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, Thomas WD Jr, Thackray LB, Young MD, Mason RJ, et al: CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 101:15748–15753. 2004. View Article : Google Scholar : PubMed/NCBI

McKee DL, Sternberg A, Stange U, Laufer S and Naujokat C: Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 157:1048592020. View Article : Google Scholar : PubMed/NCBI

Stahlmann R and Lode H: Medication for COVID-19-an over-view of approaches currently under study. Dtsch Arztebl Int. 117:213–219. 2020.PubMed/NCBI

Kupferschmidt K and Cohen J: Race to find COVID-19 treatments accelerates. Science. 367:1412–1413. 2020. View Article : Google Scholar : PubMed/NCBI

Yip CC, Ho CC, Chan JF, To KK, Chan HS, Wong SC, Leung KH, Fung AY, Ng AC, Zou Z, et al: Development of a novel, genome subtraction-derived, SARS-CoV-2-specific COVID-19-nsp2 real-time RT-PCR assay and its evaluation using clinical specimens. Int J Mol Sci. 21:25742020. View Article : Google Scholar :

Yan C, Cui J, Huang L, Du B, Chen L, Xue G, Li S, Zhang W, Zhao L, Sun Y, et al: Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. Clin Microbiol Infect. 26:773–779. 2020. View Article : Google Scholar : PubMed/NCBI

Rahman H, Carter I, Basile K, Donovan L, Kumar S, Tran T, Ko D, Alderson S, Sivaruban T, Eden JS, et al: Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus. J Clin Virol. 127:1043742020. View Article : Google Scholar : PubMed/NCBI

Pujadas E, Ibeh N, Hernandez MM, Waluszko A, Sidorenko T, Flores V, Shiffrin B, Chiu N, Young-Francois A, Nowak MD, et al: Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas(R) 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. J Med Virol. May 8–2020.Epub ahead of print. View Article : Google Scholar

Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, Carbone V, Vandenberg O, Gulbis B, Wolff F and Rodriguez-Villalobos H: Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol. 128:1044132020. View Article : Google Scholar : PubMed/NCBI

Thabet L, Mhalla S, Naija H, Jaoua MA, Hannachi N, Fki-Berrajah L, Toumi A and Karray-Hakim H: SARS-CoV-2 infection virological diagnosis. Tunis Med. 98:304–308. 2020.PubMed/NCBI

Vásárhelyi B, Kristóf K, Ostorházi E, Szabó D, Prohászka Z and Merkely B: The diagnostic value of rapid anti IgM and IgG detecting tests in the identification of patients with SARS CoV-2 virus infection. Orv Hetil. 161:807–812. 2020.In Hungarian. View Article : Google Scholar : PubMed/NCBI

Green K, Graziadio S, Turner P, Fanshawe T and Allen J: Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19. Centre for Evidence- Based Medicine (CEBM); Oxford; 2020, https://www.cebm.net/covid-19/molecular-and-antibody-point-of-care-tests-to-support-the-screening-diagnosis-and-monitoring-of-covid-19/urisimplehttps://www.cebm.net/covid-19/molecular-and-antibody-point-of-care-tests-to-support-the-screening-diagnosis-and-monitoring-of-covid-19/. Accessed April 7, 2020.

Xue X, Zhu C, Huang S, Pan L, Xu J and Li W: Effect of heat inactivation of blood samples on the efficacy of three detection methods of SARS-CoV-2 antibodies. Nan Fang Yi Ke Da Xue Xue Bao. 40:316–320. 2020.In Chinese. PubMed/NCBI

Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, Hu X, Chen J and Liu B: Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 295:22–23. 2020. View Article : Google Scholar : PubMed/NCBI

Wang P: Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections. J Virol Methods. 283:1139192020. View Article : Google Scholar : PubMed/NCBI

Lange C, Wolf J, Auw-Haedrich C, Schlecht A, Boneva S, Lapp T, Horres R, Agostini H, Martin G, Reinhard T and Schlunck G: Expression of the COVID-19 receptor ACE2 in the human conjunctiva. J Med Virol. May 6–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

Zhou J, Li C, Liu X, Chiu MC, Zhao X, Wang D, Wei Y, Lee A, Zhang AJ, Chu H, et al: Infection of bat and human intestinal organoids by SARS-CoV-2. Nat Med. 26:1077–1083. 2020. View Article : Google Scholar : PubMed/NCBI

Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, et al: SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 181:1016–1035.e19. 2020. View Article : Google Scholar : PubMed/NCBI

Rahman N, Basharat Z, Yousuf M, Castaldo G, Rastrelli L and Khan H: Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules. 25:22712020. View Article : Google Scholar :

Huang J, Song W, Huang H and Sun Q: Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: From mechanistic studies to clinical trials for COVID-19. J Clin Med. 9:11312020. View Article : Google Scholar :

ClinicalTrials.gov: NUnlom: COVID-19. https://clinicaltrials.gov/ct2/results?cond=covid-19urisimplehttps://clinicaltrials.gov/ct2/results?cond=covid-19. Accessed August 17, 2020.

Amawi H, Abu Deiab GI, A Aljabali AA, Dua K and Tambuwala MM: COVID-19 pandemic: An overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 11:245–268. 2020. View Article : Google Scholar : PubMed/NCBI

Vankadari N: Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 56:1059982020. View Article : Google Scholar : PubMed/NCBI

Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J and Xue Y: Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 81:e21–e23. 2020. View Article : Google Scholar : PubMed/NCBI

Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z and Xia J: Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 81:e1–e5. 2020. View Article : Google Scholar : PubMed/NCBI

Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, et al: The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 6:282020. View Article : Google Scholar : PubMed/NCBI

Dong L, Hu S and Gao J: Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 14:58–60. 2020. View Article : Google Scholar : PubMed/NCBI

Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ and White JM: Arbidol and other low-molecular-weight drugs that inhibit lassa and Ebola viruses. J Virol. 93:e02185–18. 2019. View Article : Google Scholar : PubMed/NCBI

Kadam RU and Wilson IA: Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci USA. 114:206–214. 2017. View Article : Google Scholar

Zeng LY, Yang J and Liu S: Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs. 26:63–73. 2017. View Article : Google Scholar

Roshanravan N, Ghaffari S and Hedayati M: Angiotensin converting enzyme-2 as therapeutic target in COVID-19. Diabetes Metab Syndr. 14:637–639. 2020. View Article : Google Scholar : PubMed/NCBI

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G and van Goor H: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 203:631–637. 2004. View Article : Google Scholar : PubMed/NCBI

Xu J and Lazartigues E: Expression of ACE2 in human neurons supports the neuro-invasive potential of COVID-19 virus. Cell Mol Neurobiol. Jul 4–2020.Epub ahead of print. View Article : Google Scholar :

Wedell J, Banzhaf G, Meier zu Eissen P and Schlageter M: Experiences with a subcutaneous, fully resorbable bridge in construction a double loop ileo- and colostomy. Chirurg. 61:36–38. 1990.In German. PubMed/NCBI

Li MY, Li L, Zhang Y and Wang XS: Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 9:452020. View Article : Google Scholar : PubMed/NCBI

Zhang X, Zheng J, Yan Y, Ruan Z, Su Y, Wang J, Huang H, Zhang Y, Wang W, Gao J, et al: Angiotensin-converting enzyme 2 regulates autophagy in acute lung injury through AMPK/mTOR signaling. Arch Biochem Biophys. 672:1080612019. View Article : Google Scholar : PubMed/NCBI

de Moraes PL, Kangussu LM, Castro CH, Almeida AP, Santos RAS and Ferreira AJ: Vasodilator effect of angiotensin-(17) on vascular coronary bed of rats: Role of Mas, ACE and ACE2. Protein Pept Lett. 24:869–875. 2017. View Article : Google Scholar : PubMed/NCBI

Basu R, Poglitsch M, Yogasundaram H, Thomas J, Rowe BH and Oudit GY: Roles of angiotensin peptides and recombinant human ACE2 in heart failure. J Am Coll Cardiol. 69:805–819. 2017. View Article : Google Scholar : PubMed/NCBI

Qiao B and Olvera de la Cruz M: Enhanced binding of SARS-CoV-2 spike protein to receptor by distal polybasic cleavage sites. ACS Nano. 14:10616–10623. 2020. View Article : Google Scholar : PubMed/NCBI

Kruse RL: Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 9:722020. View Article : Google Scholar : PubMed/NCBI

Zhang H, Penninger JM, Li Y, Zhong N and Slutsky AS: Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 46:586–590. 2020. View Article : Google Scholar : PubMed/NCBI

Mejia Torres RE, Banegas EI, Mendoza M, Diaz C, Bucheli ST, Fontecha GA, Alam MT, Goldman I, Udhayakumar V and Zambrano JO: Efficacy of chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in Honduras. Am J Trop Med Hyg. 88:850–854. 2013. View Article : Google Scholar : PubMed/NCBI

Taherian E, Rao A, Malemud CJ and Askari AD: The biological and clinical activity of anti-malarial drugs in autoimmune disorders. Curr Rheumatol Rev. 9:45–62. 2013. View Article : Google Scholar : PubMed/NCBI

Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, Pullen MF, Rajasingham R, McDonald EG, Lee TC, et al: Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 7:ofaa1302020. View Article : Google Scholar : PubMed/NCBI

Piszczatoski CR and Powell J: Emergency approval of chloroquine and hydroxychloroquine for treatment of COVID-19. Ann Pharmacother. 54:827–831. 2020. View Article : Google Scholar : PubMed/NCBI

Shukla AM, Archibald LK, Shukla AW, Mehta HJ and Cherabuddi K: Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs Context. 9(2020)–4. –5. 2020. View Article : Google Scholar

Sturrock BR and Chevassut TJ: Chloroquine and COVID-19-a potential game changer? Clin Med (Lond). 20:278–281. 2020. View Article : Google Scholar

Colson P, Rolain JM, Lagier JC, Brouqui P and Raoult D: Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 55:1059322020. View Article : Google Scholar : PubMed/NCBI

Annangi S: Chloroquine and hydroxychloroquine for COVID-19: A word of caution. Respirology. 25:683–684. 2020. View Article : Google Scholar : PubMed/NCBI

Ferner RE and Aronson JK: Chloroquine and hydroxychloroquine in covid-19. BMJ. 369:m14322020. View Article : Google Scholar : PubMed/NCBI

Badyal DK and Mahajan R: Chloroquine: Can it be a novel drug for COVID-19. Int J Appl Basic Med Res. 10:128–130. 2020.PubMed/NCBI

Hu TY, Frieman M and Wolfram J: Insights from nano-medicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 15:247–249. 2020. View Article : Google Scholar : PubMed/NCBI

Ren Y, Yao MC, Huo XQ, Gu Y, Zhu WX, Qiao YJ and Zhang YL: Study on treatment of 'cytokine storm' by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway. Zhongguo Zhong Yao Za Zhi. 45:1225–1231. 2020.In Chinese. PubMed/NCBI

McGonagle D, Sharif K, O'Regan A and Bridgewood C: The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 19:1025372020. View Article : Google Scholar : PubMed/NCBI

Lagunas-Rangel FA and Chávez-Valencia V: High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients. J Med Virol. Apr 16–2020.Epub ahead of print. View Article : Google Scholar

Aizawa T, Imaizumi T, Hirono K, Watanabe S, Tsugawa K and Tanaka H: Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells. Clin Exp Nephrol. 23:448–454. 2019. View Article : Google Scholar

Clancy RM, Markham AJ, Reed JH, Blumenberg M, Halushka MK and Buyon JP: Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block. J Autoimmun. 67:36–45. 2016. View Article : Google Scholar :

Mahase E: Hydroxychloroquine for covid-19: The end of the line? BMJ. 369:m23782020. View Article : Google Scholar : PubMed/NCBI

Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, et al: An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. May 11–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

Ahsan W, Javed S, Bratty MA, Alhazmi HA and Najmi A: Treatment of SARS-CoV-2: How far have we reached? Drug Discov Ther. 14:67–72. 2020. View Article : Google Scholar : PubMed/NCBI

Du YX and Chen XP: Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 108:242–247. 2020. View Article : Google Scholar : PubMed/NCBI

Reina J: Remdesivir, the antiviral hope against SARS-CoV-2. Rev Esp Quimioter. 33:176–179. 2020.In Spanish. View Article : Google Scholar : PubMed/NCBI

Cao YC, Deng QX and Dai SX: Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 35:1016472020. View Article : Google Scholar : PubMed/NCBI

Augustin M, Hallek M and Nitschmann S: Remdesivir for patients with severe COVID-19. Internist (Berl). 61:644–645. 2020.In German. View Article : Google Scholar

Li Z, Wang X, Cao D, Sun R, Li C and Li G: Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther. 14:73–76. 2020. View Article : Google Scholar : PubMed/NCBI

Jean SS, Lee PI and Hsueh PR: Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 53:436–443. 2020. View Article : Google Scholar : PubMed/NCBI

Lu CC, Chen MY, Lee WS and Chang YL: Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 83:534–536. 2020. View Article : Google Scholar : PubMed/NCBI

Simsek Yavuz S and Ünal S: Antiviral treatment of COVID-19. Turk J Med Sci. 50:611–619. 2020. View Article : Google Scholar : PubMed/NCBI

Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X, et al: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178:1047862020. View Article : Google Scholar : PubMed/NCBI

U.S. Food & Drug Administration (FDA): Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatmenturisimplehttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed May 1, 2020.

Chan KW, Wong VT and Tang SCW: COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and Guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 48:737–762. 2020. View Article : Google Scholar : PubMed/NCBI

Martinez MA: Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 64:e0039920–2020. View Article : Google Scholar : PubMed/NCBI

Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F, et al: COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 116:1666–1687. 2020. View Article : Google Scholar : PubMed/NCBI

Elfiky AA: Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 253:1175922020. View Article : Google Scholar : PubMed/NCBI

Elfiky AA: Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 248:1174772020. View Article : Google Scholar : PubMed/NCBI

Costanzo M, De Giglio MAR and Roviello GN: SARS-CoV-2: Recent reports on antiviral therapies based on lopinavir/rito-navir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 27:4536–4541. 2020. View Article : Google Scholar

Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, Chen W, Wang XF, Zhang WW, Du WJ, et al: Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 24:3390–3396. 2020.PubMed/NCBI

Sallard E, Lescure FX, Yazdanpanah Y, Mentre F and Peiffer-Smadja N: Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 178:1047912020. View Article : Google Scholar : PubMed/NCBI

Sauñe PM, Bryce-Alberti M, Portmann-Baracco AS and Accinelli RA: Methylprednisolone pulse therapy: An alternative management of severe COVID-19. Respir Med Case Rep. 31:1012212020.PubMed/NCBI

Yang JW, Yang L, Luo RG and Xu JF: Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin Microbiol Infect. 26:1171–1177. 2020. View Article : Google Scholar :

Li SF, Gong MJ, Zhao FR, Shao JJ, Xie YL, Zhang YG and Chang HY: Type I interferons: Distinct biological activities and current applications for viral infection. Cell Physiol Biochem. 51:2377–2396. 2018. View Article : Google Scholar : PubMed/NCBI

Andreakos E and Tsiodras S: COVID-19: Lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 12:e124652020. View Article : Google Scholar : PubMed/NCBI

Du B, Qiu HB, Zhan X, Wang YS, Kang HYJ, Li XY, Wang F, Sun B and Tong ZH: Pharmacotherapeutics for the New Coronavirus Pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 43:E0122020.In Chinese.

Vidal P: Interferon α in cancer immunoediting: From elimination to escape. Scand J Immunol. 91:e128632020. View Article : Google Scholar

Nelemans T and Kikkert M: Viral innate immune evasion and the pathogenesis of emerging RNA virus infections. Viruses. 11:9612019. View Article : Google Scholar :

Abdul-Sater AA, Majoros A, Plumlee CR, Perry S, Gu AD, Lee C, Shresta S, Decker T and Schindler C: Different STAT transcription complexes drive early and delayed responses to type I IFNs. J Immunol. 195:210–216. 2015. View Article : Google Scholar : PubMed/NCBI

Langevin C, Aleksejeva E, Passoni G, Palha N, Levraud JP and Boudinot P: The antiviral innate immune response in fish: Evolution and conservation of the IFN system. J Mol Biol. 425:4904–4920. 2013. View Article : Google Scholar : PubMed/NCBI

Zhou Q, Wei XS, Xiang X, Wang X, Wang ZH, Chen V, Shannon CP, Tebbutt SJ, Kollmann TR and Fish EN: Interferon-a2b treatment for COVID-19. medRxiv. https://www.101101/2020040620042580urisimplehttps://101101/2020040620042580.

Morgenstern B, Michaelis M, Baer PC, Doerr HW and Cinatl J Jr: Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 326:905–908. 2005. View Article : Google Scholar

Mantlo E, Bukreyeva N, Maruyama J, Paessler S and Huang C: Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 179:1048112020. View Article : Google Scholar : PubMed/NCBI

Young MJ, Clyne CD and Chapman KE: Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. J Endocrinol. 247:R45–R62. 2020. View Article : Google Scholar : PubMed/NCBI

Xavier AM, Anunciato AK, Rosenstock TR and Glezer I: Gene expression control by glucocorticoid receptors during innate immune responses. Front Endocrinol (Lausanne). 7:312016. View Article : Google Scholar

Hardy RS, Raza K and Cooper MS: Therapeutic glucocorticoids: Mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 16:133–144. 2020. View Article : Google Scholar : PubMed/NCBI

Song P, Li W, Xie J, Hou Y and You C: Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 509:280–287. 2020. View Article : Google Scholar : PubMed/NCBI

Komiyama M and Hasegawa K: Anticoagulant therapy for patients with coronavirus disease 2019: Urgent need for enhanced awareness. Eur Cardiol. 15:e582020. View Article : Google Scholar : PubMed/NCBI

Merrill JT, Erkan D, Winakur J and James JA: Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 16:581–589. 2020. View Article : Google Scholar : PubMed/NCBI

Fletcher-Sandersjöö A and Bellander BM: Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb Res. 194:36–41. 2020. View Article : Google Scholar : PubMed/NCBI

Conway EM and Pryzdial ELG: Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost. Aug 6–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

Furie B and Furie BC: Mechanisms of thrombus formation. N Engl J Med. 359:938–949. 2008. View Article : Google Scholar : PubMed/NCBI

Giannis D, Ziogas IA and Gianni P: Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 127:1043622020. View Article : Google Scholar : PubMed/NCBI

Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, et al: COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art review. J Am Coll Cardiol. 75:2950–2973. 2020. View Article : Google Scholar : PubMed/NCBI

Liu J, Li J, Arnold K, Pawlinski R and Key NS: Using heparin molecules to manage COVID-2019. Res Pract Thromb Haemost. 4:518–523. 2020. View Article : Google Scholar : PubMed/NCBI

Panka BA, de Grooth HJ, Spoelstra-de Man AM, Looney MR and Tuinman PR: Prevention or treatment of ards with aspirin: A review of preclinical models and meta-analysis of clinical studies. Shock. 47:13–21. 2017. View Article : Google Scholar

Chen W, Janz DR, Bastarache JA, May AK, O'Neal HR Jr, Bernard GR and Ware LB: Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: A propensity-adjusted analysis. Crit Care Med. 43:801–807. 2015. View Article : Google Scholar : PubMed/NCBI

Li Z, Li X, Huang YY, Wu Y, Liu R, Zhou L, Lin Y, Wu D, Zhang L, Liu H, et al: Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc Natl Acad Sci USA. 117:27381–27387. 2020. View Article : Google Scholar : PubMed/NCBI

Whyte CS, Morrow GB, Mitchell JL, Chowdary P and Mutch NJ: Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 18:1548–1555. 2020. View Article : Google Scholar : PubMed/NCBI

Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, et al: Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 584:115–119. 2020. View Article : Google Scholar : PubMed/NCBI

Graham BS: Rapid COVID-19 vaccine development. Science. 368:945–946. 2020. View Article : Google Scholar : PubMed/NCBI

Shepard HM, Phillips GL, D Thanos C and Feldmann M: Developments in therapy with monoclonal antibodies and related proteins. Clin Med (Lond). 17:220–232. 2017. View Article : Google Scholar

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M and Mayhew S: The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 19:305–306. 2020. View Article : Google Scholar : PubMed/NCBI

Corey L, Mascola JR, Fauci AS and Collins FS: A strategic approach to COVID-19 vaccine R&D. Science. 368:948–950. 2020. View Article : Google Scholar : PubMed/NCBI

Zhao Z, Li Y, Zhou L, Zhou X, Xie B, Zhang W and Sun J: Prevention and treatment of COVID-19 using Traditional Chinese Medicine: A review. Phytomedicine. 153308:2020.

Zhang YS, Cong WH, Zhang JJ, Guo FF and Li HM: Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus. Zhongguo Zhong Yao Za Zhi. 45:1263–1271. 2020.In Chinese. PubMed/NCBI

McKimm-Breschkin JL, Jiang S, Hui DS, Beigel JH, Govorkova EA and Lee N: Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antiviral Res. 149:118–142. 2018. View Article : Google Scholar

Teschke R, Larrey D, Melchart D and Danan G: Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as MicroRNAs. Medicines (Basel). 3. pp. 182016, View Article : Google Scholar

Hu XY, Logue M and Robinson N: Antimicrobial resistance is a global problem - a UK perspective. Eur J Integr Med. 36:1011362020. View Article : Google Scholar : PubMed/NCBI

Ho LTF, Chan KKH, Chung VCH and Leung TH: Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. Eur J Integr Med. 36:1011162020. View Article : Google Scholar : PubMed/NCBI

Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, Pizarro G, Vial P, Iruretagoyena M, Dittrich S and Weitzel T: Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. Int J Infect Dis. 99:328–333. 2020. View Article : Google Scholar : PubMed/NCBI

Mirijello A, D'Errico MM, Lamarca A, Piscitelli P and De Cosmo S: Comment on Matricardi PM et al: The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol. May 17–2020.Epub ahead of print. View Article : Google Scholar